Growth Insights on China’s Pharmaceutical Industry, Forecast to 2025

Growth Insights on China’s Pharmaceutical Industry, Forecast to 2025

Expedited Regulatory Reviews, Accompanied by Surging Novel Drug Pipelines and a Realigned Distribution System will Propel the Chinese Pharma Industry

RELEASE DATE
10-Jan-2020
REGION
Asia Pacific
Research Code: PAB8-01-00-00-00
SKU: HC03249-AP-MR_23910

$10,000.00

Special Price $7,500.00 save 25 %

In stock
SKU
HC03249-AP-MR_23910

$10,000.00

$7,500.00 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10% of the market. The market being highly dependent on its distributor networks, leading pharma players including Sinopharm and Shanghai Pharmaceuticals have a strong control on these networks.

In line with the changing market trends, the Chinese Government is increasingly focused on changing its status from an imitator to innovator, by propelling its biologics pipeline. At present, the country holds a pipeline of over 700 molecules. Also, this transition calls for greater technological advancements in the form of advanced manufacturing technologies such as single use and continuous manufacturing processes, which are essentially aimed at supporting the changing trend of small volume-high value manufacturing. As a result, the industry is witnessing a consolidation spree with over 243 deals witnessed in early 2019.

Inspite of a budding innovator drug industry, the Chinese Government is equally focused on promoting and supporting its 2000-year old Traditional Chinese Medicine (TCM) market with the issuance of the ‘Outline of the Strategic Plan on the Development of Traditional Chinese Medicine (2016-2030)’, making TCM development a national strategy, as a part of the Healthy China 2030 initiative. The Government plans to release new standards for 150-200 concentrated TCM Granules (CTCMG), that are likely to facilitate a strong market growth. In addition, other APAC countries including Japan have raised precise guidelines regarding the use of correct ingredients and processing of TC products in Japan, which will further propel the segment growth.

The present growth insights study for China’s Pharmaceuticals Industry covers some of the leading industry trends across the Chinese pharma market while highlighting the impact of the changing regulatory landscape on individual segments. Also, the study provides a deep-dive analysis on industry segments including small molecules, OTC, TCM, and Biologics (innovator vs. biosimilars).

Key Issues Addressed

  • What are the key market trends supporting the expansion of the Chinese pharmaceutical industry?
  • What are the leading markets segments supporting market growth? How will they impact market growth in the future?
  • Who are the leading market participants in the market and what is their contribution to the market progression?
  • What are the major growth opportunities across the market? What kind of impact would these have on the market growth?
  • What are the key regulatory and pricing changes across the Chinese pharma market? How are these changes expected to affect the market in the long run?

Author: Khushbu Jain

Table of Contents

Purpose of this Experiential Study

5-Step Process to Transformational Growth

Market Engineering Measurements

Scope and Segmentation

Key Questions to be Answered

China’s Pharmaceutical Industry—Market Overview

Leading Trends Driving the Chinese Pharmaceutical Industry

Drivers and Restraints

Reforms Leading to Transformation in the Industry

Reforms Leading to Transformation in the Industry (continued)

Transitioning Reimbursement Landscape

Shift towards a Commercial Insurance Model

Changing Dynamics of Distributor Networks

Market Engineering Measurements

Forecast Assumptions

Revenue Forecast—Total Pharmaceutical Market

Revenue Forecast—By Segments

Revenue Forecast Discussion

Market Share Analysis

Revenue Forecast—Small Molecule

Revenue Forecast—Biologics Segment

Revenue Forecast—Therapeutic Biologics by Segments

Revenue Forecast Discussion by Segments

Biologics Pipeline in Collaboration with Biopharma

Pharmaceutical Commercial Landscape

4 Major Growth Opportunities

Growth Opportunity 1—Intermediates and Fine Chemicals for Pharma Manufacturing

Growth Opportunity 2—Innovative Biologic Pipeline Bridging the Gap with Regulated Markets

Bridging the Gap with Regulated Markets

Growth Opportunity 3—Thriving CDMO Industry Attracting Pharma Investments

Measures Taken by CDMO/CRO Participants to Attract Investments

Growth Opportunity 4—Biosimilar Co-Development for Oncology

Policy Changes to Support Biosimilar Development

Strategic Imperatives for Growth

Conclusion

Legal Disclaimer

List of Exhibits

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor networks, leading pharma players including Sinopharm and Shanghai Pharmaceuticals have a strong control on these networks. In line with the changing market trends, the Chinese Government is increasingly focused on changing its status from an imitator to innovator, by propelling its biologics pipeline. At present, the country holds a pipeline of over 700 molecules. Also, this transition calls for greater technological advancements in the form of advanced manufacturing technologies such as single use and continuous manufacturing processes, which are essentially aimed at supporting the changing trend of small volume-high value manufacturing. As a result, the industry is witnessing a consolidation spree with over 243 deals witnessed in early 2019. Inspite of a budding innovator drug industry, the Chinese Government is equally focused on promoting and supporting its 2000-year old Traditional Chinese Medicine (TCM) market with the issuance of the ‘Outline of the Strategic Plan on the Development of Traditional Chinese Medicine (2016-2030)’, making TCM development a national strategy, as a part of the Healthy China 2030 initiative. The Government plans to release new standards for 150-200 concentrated TCM Granules (CTCMG), that are likely to facilitate a strong market growth. In addition, other APAC countries including Japan have raised precise guidelines regarding the use of correct ingredients and processing of TC products in Japan, which will further propel the segment growth. The present growth insights study for China’s Pharmaceuticals Industry covers some of the leading industry trends across the Chinese pharma market while highlighting the impact of the changing regulatory landscape on individual segments. Also, the study provides a deep-dive analysis on industry segments including small molecules, OTC, TCM, and Biologics (innovator vs. biosimilars).--BEGIN PROMO--

Key Issues Addressed

  • What are the key market trends supporting the expansion of the Chinese pharmaceutical industry?
  • What are the leading markets segments supporting market growth? How will they impact market growth in the future?
  • Who are the leading market participants in the market and what is their contribution to the market progression?
  • What are the major growth opportunities across the market? What kind of impact would these have on the market growth?
  • What are the key regulatory and pricing changes across the Chinese pharma market? How are these changes expected to affect the market in the long run?

Author: Khushbu Jain

More Information
No Index No
Podcast No
Author Aarti Chitale
Industries Healthcare
WIP Number PAB8-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,99C1-B1,9611-B1